Eli Lilly and Company (NEO:LLY)

Market Cap	903.04B
Revenue (ttm)	72.64B
Net Income (ttm)	18.82B
Shares Out	n/a
EPS (ttm)	20.86
PE Ratio	47.98
Forward PE	25.88
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82,384
Average Volume	100,254
Open	27.12
Previous Close	27.16
Day's Range	26.47 - 27.12
52-Week Range	22.85 - 35.28
Beta	0.44
RSI	49.99
Earnings Date	Oct 30, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Cboe Canada
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD